158 related articles for article (PubMed ID: 27740776)
1. Oral Delivery of a Nanocrystal Formulation of Schisantherin A with Improved Bioavailability and Brain Delivery for the Treatment of Parkinson's Disease.
Chen T; Li C; Li Y; Yi X; Lee SM; Zheng Y
Mol Pharm; 2016 Nov; 13(11):3864-3875. PubMed ID: 27740776
[TBL] [Abstract][Full Text] [Related]
2. Small-Sized mPEG-PLGA Nanoparticles of Schisantherin A with Sustained Release for Enhanced Brain Uptake and Anti-Parkinsonian Activity.
Chen T; Li C; Li Y; Yi X; Wang R; Lee SM; Zheng Y
ACS Appl Mater Interfaces; 2017 Mar; 9(11):9516-9527. PubMed ID: 28247754
[TBL] [Abstract][Full Text] [Related]
3. Oral Delivery of Puerarin Nanocrystals To Improve Brain Accumulation and Anti-Parkinsonian Efficacy.
Xiong S; Liu W; Li D; Chen X; Liu F; Yuan D; Pan H; Wang Q; Fang S; Chen T
Mol Pharm; 2019 Apr; 16(4):1444-1455. PubMed ID: 30811206
[TBL] [Abstract][Full Text] [Related]
4. Discovery of novel anti-parkinsonian effect of schisantherin A in in vitro and in vivo.
Sa F; Zhang LQ; Chong CM; Guo BJ; Li S; Zhang ZJ; Zheng Y; Hoi PM; Lee SM
Neurosci Lett; 2015 Apr; 593():7-12. PubMed ID: 25770828
[TBL] [Abstract][Full Text] [Related]
5. Polymeric Nanoparticles-Based Brain Delivery with Improved Therapeutic Efficacy of Ginkgolide B in Parkinson's Disease.
Zhao Y; Xiong S; Liu P; Liu W; Wang Q; Liu Y; Tan H; Chen X; Shi X; Wang Q; Chen T
Int J Nanomedicine; 2020; 15():10453-10467. PubMed ID: 33380795
[TBL] [Abstract][Full Text] [Related]
6. Schisandra lignans-loaded enteric nanoparticles: preparation, characterization, and in vitro-in vivo evaluation.
Pei J; Lv Q; Han J; Li X; Jin S; Huang Y; Jin S; Yuan H
J Drug Target; 2013 Feb; 21(2):180-7. PubMed ID: 23373544
[TBL] [Abstract][Full Text] [Related]
7. Improved oral bioavailability for lutein by nanocrystal technology: formulation development, in vitro and in vivo evaluation.
Chang D; Ma Y; Cao G; Wang J; Zhang X; Feng J; Wang W
Artif Cells Nanomed Biotechnol; 2018 Aug; 46(5):1018-1024. PubMed ID: 28749189
[TBL] [Abstract][Full Text] [Related]
8. Anti-apoptotic effect of modified Chunsimyeolda-tang, a traditional Korean herbal formula, on MPTP-induced neuronal cell death in a Parkinson's disease mouse model.
Li H; Park G; Bae N; Kim J; Oh MS; Yang HO
J Ethnopharmacol; 2015 Dec; 176():336-44. PubMed ID: 26593210
[TBL] [Abstract][Full Text] [Related]
9. Nanoparticles Mediating the Sustained Puerarin Release Facilitate Improved Brain Delivery to Treat Parkinson's Disease.
Chen T; Liu W; Xiong S; Li D; Fang S; Wu Z; Wang Q; Chen X
ACS Appl Mater Interfaces; 2019 Dec; 11(48):45276-45289. PubMed ID: 31638771
[TBL] [Abstract][Full Text] [Related]
10. Schisantherin A suppresses osteoclast formation and wear particle-induced osteolysis via modulating RANKL signaling pathways.
He Y; Zhang Q; Shen Y; Chen X; Zhou F; Peng D
Biochem Biophys Res Commun; 2014 Jul; 449(3):344-50. PubMed ID: 24845381
[TBL] [Abstract][Full Text] [Related]
11. Schisantherin A recovers Aβ-induced neurodegeneration with cognitive decline in mice.
Li X; Zhao X; Xu X; Mao X; Liu Z; Li H; Guo L; Bi K; Jia Y
Physiol Behav; 2014 Jun; 132():10-6. PubMed ID: 24813830
[TBL] [Abstract][Full Text] [Related]
12. Schisantherin A protects against 6-OHDA-induced dopaminergic neuron damage in zebrafish and cytotoxicity in SH-SY5Y cells through the ROS/NO and AKT/GSK3β pathways.
Zhang LQ; Sa F; Chong CM; Wang Y; Zhou ZY; Chang RC; Chan SW; Hoi PM; Yuen Lee SM
J Ethnopharmacol; 2015 Jul; 170():8-15. PubMed ID: 25934514
[TBL] [Abstract][Full Text] [Related]
13. [Effect of schisantherin A inhibit liver sinusoid endothelial cell function and action against liver fibrosis relating to angiogenesis].
Zhu CW; Lv J; Zhao ZM; Tao YY; Liu CH
Zhongguo Zhong Yao Za Zhi; 2016 Jan; 41(2):279-284. PubMed ID: 28861974
[TBL] [Abstract][Full Text] [Related]
14. Formulation of 20(S)-protopanaxadiol nanocrystals to improve oral bioavailability and brain delivery.
Chen C; Wang L; Cao F; Miao X; Chen T; Chang Q; Zheng Y
Int J Pharm; 2016 Jan; 497(1-2):239-47. PubMed ID: 26680316
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and pharmacodynamics of intranasally administered selegiline nanoparticles with improved brain delivery in Parkinson's disease.
Sridhar V; Gaud R; Bajaj A; Wairkar S
Nanomedicine; 2018 Nov; 14(8):2609-2618. PubMed ID: 30171904
[TBL] [Abstract][Full Text] [Related]
16. Highly stabilized nanocrystals delivering Ginkgolide B in protecting against the Parkinson's disease.
Liu Y; Liu W; Xiong S; Luo J; Li Y; Zhao Y; Wang Q; Zhang Z; Chen X; Chen T
Int J Pharm; 2020 Mar; 577():119053. PubMed ID: 31981707
[TBL] [Abstract][Full Text] [Related]
17. The Chinese herbal formula Liuwei dihuang protects dopaminergic neurons against Parkinson's toxin through enhancing antioxidative defense and preventing apoptotic death.
Tseng YT; Chang FR; Lo YC
Phytomedicine; 2014 Apr; 21(5):724-33. PubMed ID: 24411708
[TBL] [Abstract][Full Text] [Related]
18. [Preparation of enteric nanoparticles of Schisandra total lignanoids and preliminary study on its pharmacokinetics].
Huang YJ; Li YB; Yuan HL; Huang X; Wang Q; Xiao XH
Yao Xue Xue Bao; 2009 Sep; 44(9):1046-50. PubMed ID: 20055183
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic study of schisandrin, schisandrol B, schisantherin A, deoxyschisandrin, and schisandrin B in rat plasma after oral administration of Shengmaisan formula by UPLC-MS.
Sun H; Wu F; Zhang A; Wei W; Han Y; Wang X
J Sep Sci; 2013 Feb; 36(3):485-91. PubMed ID: 23303577
[TBL] [Abstract][Full Text] [Related]
20. Dihydromyricetin protects neurons in an MPTP-induced model of Parkinson's disease by suppressing glycogen synthase kinase-3 beta activity.
Ren ZX; Zhao YF; Cao T; Zhen XC
Acta Pharmacol Sin; 2016 Sep; 37(10):1315-1324. PubMed ID: 27374489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
